Analysis of GLP-1 Agonists Using the Agilent 1290 Infinity II Bio LC System and Altura Ultra Inert HPLC Column

Poster Reprint ASMS 2026 TP 407 Integrated LC/UV and LC/MS Workflows for Impurity and Degradation Characterization of GLP-1 Agonists David L. Wong1 , Suresh Babu C.V.2 1Agilent Technologies, Inc., Santa Clara, CA, USA 2Agilent Technologies, Singapore Introduction Synthetic peptide therapeutics…

Application Note Biopharma Therapeutic Peptide Analysis of GLP‑1 Agonists Using an Agilent Altura Peptide Plus column and an Agilent InfinityLab Pro iQ Plus Author Abstract Suresh Babu C.V. Agilent Technologies, Inc. The biopharmaceutical industry requires analytical control of synthetic peptide…

Agilent biopharma solutions Workflows for GLP-1 Receptor Agonists and Therapeutic Peptides: Identity, Impurity, Bioanalysis, and Stability Testing Contents Raw Material Purity and Impurity Identification Analysis Bioanalysis Stability Testing Studies Contents Introduction 02 1 Raw Material Identification 03 1.1 Verification…

Application Note Biopharma Analytical Characterization of GLP-1 Agonists: Sequence Confirmation by Q-TOF MS/MS Author Suresh Babu C. V. Agilent Technologies, Inc. Abstract The role of synthetic peptides in modern therapeutics continues to expand, elevating the importance of rigorous sequence confirmation…